Paul L McCormack

Summary

Affiliation: Adis International Inc
Country: USA

Publications

  1. ncbi request reprint Pimecrolimus: a review of its use in atopic dermatitis
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:479-95. 2004
  2. ncbi request reprint Valsartan: in chronic heart failure
    Keri Wellington
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:267-74; discussion 275-6. 2002
  3. ncbi request reprint Efalizumab
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 6:113-8; discussion 119-20. 2005
  4. ncbi request reprint Spotlight on cefditoren pivoxil in bacterial infections
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:149-52. 2005
  5. ncbi request reprint Ipratropium bromide HFA
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:215-20; discussion 221-2. 2005
  6. doi request reprint Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure
    Karly P Garnock-Jones
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    Drugs 73:371-81. 2013
  7. pmc Immune globulin subcutaneous (human) 20%: in primary immunodeficiency disorders
    Paul L McCormack
    Adis, Auckland, New Zealand
    Drugs 72:1087-97. 2012
  8. doi request reprint Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia
    Caroline M Perry
    Adis, 41 Centorian Drive, Private Bag 65901 Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    Am J Cardiovasc Drugs 13:285-96. 2013
  9. doi request reprint Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion
    Yahiya Y Syed
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    Drugs 73:1183-96. 2013
  10. doi request reprint Teduglutide: a review of its use in the treatment of patients with short bowel syndrome
    Celeste B Burness
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 73:935-47. 2013

Collaborators

  • Katherine A Lyseng-Williamson
  • Jamie D Croxtall
  • Dean M Robinson
  • Gillian M Keating
  • Greg L Plosker
  • Monique P Curran
  • James E Frampton
  • Juliane Weber
  • Kate McKeage
  • Elmar A Joura
  • C J Dunn
  • Armando Santoro
  • Mark Sanford
  • Jean Pierre Zellweger
  • Lesley J Scott
  • M Asif A Siddiqui
  • Caroline M Perry
  • John Waugh
  • Antona J Wagstaff
  • Keri Wellington
  • Susan J Keam
  • Caroline Fenton
  • Dene Simpson
  • Marit D Moen
  • Sheridan M Hoy
  • Lynne M Bang
  • David R Goldsmith
  • Sohita Dhillon
  • Susan M Cheer
  • Celeste B Burness
  • Blair Jarvis
  • Katherine F Croom
  • Neil A Reynolds
  • Karly P Garnock-Jones
  • Stuart Noble
  • David P Figgitt
  • Karen L Goa
  • Tracy Swainston Harrison
  • Vicki Oldfield
  • Toni M Dando
  • Therese M Chapman
  • Richard B R Muijsers
  • Miriam Sharpe
  • Yahiya Y Syed
  • Emma D Deeks
  • Lily P H Yang
  • Jane K McGavin
  • Gregory T Warner
  • Claudine M Baldwin
  • Philip I Hair
  • Daniel E Hilleman
  • Vanessa R Anderson
  • Anna J Battershill
  • Jennifer S Dickie
  • Julia A Barman Balfour
  • David Murdoch
  • Ngaire J White
  • Tim Ibbotson
  • Lynne Bang
  • Karen McClellan
  • Nila Bhana
  • Amitabh Prakash
  • Gordon Mallarkey
  • Douglas Ormrod
  • Christine R Culy
  • Deborah J Cochrane
  • S E Easthope
  • E B Melian
  • B Jarvis
  • L J Scott
  • Risto S Cvetkovic
  • Stephanie Easthope
  • Jane Easton
  • Karen Goa
  • Stephanie E Easthope
  • K L Goa
  • C M Spencer

Detail Information

Publications170 found, 100 shown here

  1. ncbi request reprint Pimecrolimus: a review of its use in atopic dermatitis
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:479-95. 2004
    ..Thus, topical pimecrolimus 1% cream is an effective treatment option for the management of mild-to-moderate atopic dermatitis...
  2. ncbi request reprint Valsartan: in chronic heart failure
    Keri Wellington
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:267-74; discussion 275-6. 2002
    ..The most common adverse events in the valsartan and placebo groups which led to discontinuation of treatment were dizziness, renal impairment (both of which occurred in significantly more valsartan recipients) and hypotension...
  3. ncbi request reprint Efalizumab
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 6:113-8; discussion 119-20. 2005
    ....
  4. ncbi request reprint Spotlight on cefditoren pivoxil in bacterial infections
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:149-52. 2005
    ....
  5. ncbi request reprint Ipratropium bromide HFA
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:215-20; discussion 221-2. 2005
    ..The most common adverse events were related to respiratory system disorders. During the 1-year study, dry mouth was reported by 1.3% and 0.7% of patients in the ipratropium bromide HFA or ipratropium bromide CFC groups...
  6. doi request reprint Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure
    Karly P Garnock-Jones
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    Drugs 73:371-81. 2013
    ..Brentuximab vedotin was generally well tolerated in these trials. The most common adverse event was peripheral neuropathy; approximately one-half of patients with this adverse event experienced complete resolution...
  7. pmc Immune globulin subcutaneous (human) 20%: in primary immunodeficiency disorders
    Paul L McCormack
    Adis, Auckland, New Zealand
    Drugs 72:1087-97. 2012
    ..A high proportion of patients experienced local infusion-site reactions, but infusion-related systemic adverse events were relatively infrequent. Most adverse events were of mild or moderate intensity and did not interfere with therapy...
  8. doi request reprint Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia
    Caroline M Perry
    Adis, 41 Centorian Drive, Private Bag 65901 Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    Am J Cardiovasc Drugs 13:285-96. 2013
    ..Lomitapide was generally well tolerated; the most common adverse events in the phase III trial were gastrointestinal events. ..
  9. doi request reprint Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion
    Yahiya Y Syed
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    Drugs 73:1183-96. 2013
    ..Thus, lenalidomide is a useful option for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk del(5q) MDS, with or without additional cytogenetic abnormalities...
  10. doi request reprint Teduglutide: a review of its use in the treatment of patients with short bowel syndrome
    Celeste B Burness
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 73:935-47. 2013
    ....
  11. doi request reprint Crotalidae polyvalent immune Fab: a guide to its use in North American crotaline envenomation
    Gillian M Keating
    Adis, Auckland, New Zealand
    Clin Drug Investig 32:555-60. 2012
    ..g. coagulopathy). Intravenous crotalidae polyvalent immune Fab is generally well tolerated, with acute hypersensitivity reactions being the most commonly occurring adverse event...
  12. doi request reprint Polyphenon E 10% ointment: in immunocompetent adults with external genital and perianal warts
    Sheridan M Hoy
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Am J Clin Dermatol 13:275-81. 2012
    ..According to pooled data from the two clinical studies, the majority of adverse events associated with polyphenon E 10% ointment involved application site and local skin reactions at the treatment site...
  13. doi request reprint Ulipristal acetate: in uterine fibroids
    Jamie D Croxtall
    Adis, Auckland, New Zealand
    Drugs 72:1075-85. 2012
    ..Ulipristal acetate was generally well tolerated in women with uterine fibroids. The incidence of hot flush occurred with a significantly lower frequency for recipients of ulipristal acetate than for recipients of leuprolide acetate...
  14. doi request reprint Intravenous ibuprofen: in adults for pain and fever
    Lesley J Scott
    Adis, Auckland, New Zealand
    Drugs 72:1099-109. 2012
    ..Intravenous ibuprofen was generally well tolerated by hospitalized adult patients participating in these clinical trials. The most common adverse event leading to discontinuation of ibuprofen treatment was pruritus (<1% of patients)...
  15. doi request reprint Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia
    Gillian M Keating
    Adis, Auckland, New Zealand
    Drugs 72:1111-36. 2012
    ..g. nausea, vomiting and diarrhoea) and injection-site reactions among the most commonly occurring non-haematological adverse events. In conclusion, azacitidine is an important agent for use in the treatment of patients with MDS/AML...
  16. doi request reprint Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US
    Katherine A Lyseng-Williamson
    Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 12:207-16. 2012
    ..Limited pharmacoeconomic analyses suggest that prasugrel-based therapy is an economically attractive treatment strategy relative to clopidogrel-based therapy from a US healthcare payer perspective...
  17. doi request reprint Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria
    Gillian M Keating
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 72:937-61. 2012
    ..In conclusion, dihydroartemisinin/piperaquine is a valuable option for use in the first-line treatment of uncomplicated P. falciparum malaria...
  18. doi request reprint Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
    Sohita Dhillon
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 72:917-30. 2012
    ..Bevacizumab combination therapy had generally acceptable tolerability in these studies, with the nature of adverse events generally similar to that observed in previous clinical trials in patients with other solid tumours...
  19. doi request reprint Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery
    Celeste B Burness
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 72:963-86. 2012
    ..In the meantime, dabigatran etexilate offers a convenient, effective and generally well tolerated treatment option for the prophylaxis of VTE in patients undergoing TKR and THR surgery...
  20. doi request reprint Quetiapine: a review of its use in the management of bipolar depression
    Mark Sanford
    Adis, Auckland, New Zealand
    CNS Drugs 26:435-60. 2012
    ..Further head-to-head trials of quetiapine versus other drug regimens that are effective in bipolar depression would be of considerable interest...
  21. ncbi request reprint Atomoxetine
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:407-15; discussion 416-7. 2003
    ..The most common treatment-related adverse event was decreased appetite. Atomoxetine shows no abuse potential and is not a controlled substance in the US...
  22. ncbi request reprint Poly-L-lactic acid
    Caroline M Perry
    Adis International Inc Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:361-6; discussion 367-8. 2004
    ..Poly-L-lactic acid was generally well tolerated. No serious adverse events were reported...
  23. ncbi request reprint Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne
    Gregory T Warner
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Clin Dermatol 3:349-60. 2002
    ..The most common adverse events were dry skin, peeling, erythema and rash; however, adverse event-caused treatment discontinuation rates for patients using clindamycin/benzoyl peroxide were low, ranging from 0 to 0.8%...
  24. ncbi request reprint Spotlight on etanercept in plaque psoriasis and psoriatic arthritis
    David R Goldsmith
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:401-3. 2005
    ....
  25. ncbi request reprint Anakinra: a review of its use in the management of rheumatoid arthritis
    John Waugh
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:189-202. 2005
    ..It is subcutaneously administered and is generally well tolerated. Anakinra offers a useful addition to the range of drugs available for the treatment of RA...
  26. ncbi request reprint Alefacept
    James Frampton
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Clin Dermatol 4:277-86; discussion 287. 2003
    ..No opportunistic infections have been reported, nor is there evidence of an increased risk of malignancies...
  27. ncbi request reprint Extended-release metformin hydrochloride. Single-composition osmotic tablet formulation
    Antona J Wagstaff
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 3:327-32. 2004
    ..Like the IR formulation, metformin XT is generally well tolerated; gastro-intestinal adverse events are, however, common...
  28. ncbi request reprint Spotlight on rosiglitazone in the management of type 2 diabetes mellitus
    Antona J Wagstaff
    Adis International Inc, Langhorne, Pennsylvania, USA
    Treat Endocrinol 1:411-4. 2002
    ..Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus...
  29. ncbi request reprint Lucinactant: in neonatal respiratory distress syndrome
    Marit D Moen
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:139-45; discussion 146-7. 2005
    ..Adverse events were transient and related to the administration procedure. There were no differences in the incidences of complications of prematurity between lucinactant and the other surfactants...
  30. ncbi request reprint Reteplase: a review of its use in the management of thrombotic occlusive disorders
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 6:265-85. 2006
    ....
  31. ncbi request reprint Lamivudine: in children and adolescents with chronic hepatitis B virus infection
    Susan J Keam
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Paediatr Drugs 4:687-94; discussion 695-6. 2002
    ..Oral lamivudine is generally well tolerated by children and adolescents with chronic hepatitis B, with a similar tolerability profile to placebo at the recommended once daily dosage of 3 mg/kg up to a maximum of 100 mg/day...
  32. ncbi request reprint Spotlight on insulin glargine in type 1 and 2 diabetes mellitus
    Kate McKeage
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 1:55-8. 2002
    ..Therefore, insulin glargine is likely to be a useful addition to the armamentarium of insulin therapy by establishing basal glycemic control with once daily administration and a reduced risk of nocturnal hypoglycemia...
  33. ncbi request reprint Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels
    Miriam Sharpe
    Adis International Limited, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:125-32; discussion 133-4. 2002
    ..In double-blind, placebo-controlled trials in a total of 804 patients, the pooled incidences of individual adverse events were generally similar with fenofibrate and placebo...
  34. ncbi request reprint Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis
    David R Goldsmith
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 6:121-36. 2005
    ....
  35. ncbi request reprint Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease
    Katherine A Lyseng-Williamson
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:273-82; discussion 283-4. 2002
    ..Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD...
  36. ncbi request reprint Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD
    Susan J Keam
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Respir Med 3:247-68. 2004
    ..Similar proportions of tiotropium, salmeterol, and placebo recipients required COPD-related hospitalizations. (ABSTRACT TRUNCATED)..
  37. ncbi request reprint Intravenous conivaptan
    Marit D Moen
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 8:341-8; discussion 349. 2008
    ..The most common adverse events were injection related (e.g. injection-site phlebitis), hypotension, and pyrexia...
  38. ncbi request reprint T-SPOT.TB: an in vitro diagnostic assay measuring T-cell reaction to Mycobacterium tuberculosis-specific antigens
    Antona J Wagstaff
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Mol Diagn Ther 10:57-63; discussion 64-5. 2006
    ..Unlike the TST, the RD1 ELISPOT assay is not confounded by bacille Calmette-Guérin vaccination...
  39. ncbi request reprint Once-monthly ibandronate
    Toni M Dando
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 4:381-7; discussion 389-90. 2005
    ..Significantly more women with osteoporosis preferred once-monthly ibandronate and found it more convenient than once-weekly alendronate, according to data from a 6-month, randomized, open-label, crossover study...
  40. ncbi request reprint The Novolizer: a multidose dry powder inhaler
    M Asif A Siddiqui
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, PA 19067, USA
    Treat Respir Med 4:63-9. 2005
    ..Overall, the Novolizer was well accepted, with an improved compliance in 80% of patients that was attributable to the control mechanisms of the device...
  41. ncbi request reprint Rosuvastatin: a review of its use in the management of dyslipidemia
    Lesley J Scott
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 4:117-38. 2004
    ..Thus, rosuvastatin has emerged as a valuable choice for first-line treatment in the management of low- to high-risk patients requiring lipid-lowering drug therapy...
  42. ncbi request reprint Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism
    Dean M Robinson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 5:335-46. 2005
    ..It thus provides a valuable alternative to UFH and low-molecular weight heparins in the treatment of acute VTE, particularly in the outpatient setting...
  43. ncbi request reprint Formoterol: a review of its use in chronic obstructive pulmonary disease
    Susan M Cheer
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:285-300. 2002
    ..Thus, inhaled formoterol may be considered as a first-line option for the management of bronchoconstriction in patients with COPD who require regular bronchodilator therapy for the management of symptoms...
  44. ncbi request reprint Losartan: in the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy
    John Waugh
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 3:371-7; discussion 378-9. 2003
    ..Significantly fewer losartan than atenolol recipients discontinued treatment because of adverse events, drug-related adverse events, or serious, drug-related adverse events...
  45. ncbi request reprint Calcipotriol ointment. A review of its use in the management of psoriasis
    L J Scott
    Adis International Inc, Langhorne, Pennsylvania, USA
    Am J Clin Dermatol 2:95-120. 2001
    ..Although data in children are limited, the drug was well tolerated with the nature and incidence of adverse effects similar to those observed in adult patients...
  46. ncbi request reprint Omalizumab: a review of its use in the management of allergic asthma
    Lynne M Bang
    Adis International Inc, Yardley, Pennsylvania 19607, USA
    Treat Respir Med 3:183-99. 2004
    ....
  47. ncbi request reprint Topical methyl aminolevulinate
    M Asif A Siddiqui
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:127-37; discussion 138-40. 2004
    ..The most frequently reported adverse events were local phototoxicity reactions, most of which were of mild to moderate intensity, resolved rapidly and were rarely treatment limiting...
  48. ncbi request reprint Alendronate/colecalciferol
    Neil A Reynolds
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 4:371-7; discussion 379. 2005
    ..The treatment-related adverse event profile of once-weekly alendronate/colecalciferol 70 mg/2800 IU was similar to that of once-weekly alendronate in the 15-week, double-blind study in patients with osteoporosis...
  49. ncbi request reprint Spotlight on zanamivir in influenza
    Susan M Cheer
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:147-52. 2002
    ..Zanamivir shows potential for prophylaxis in persons for whom vaccination is contraindicated or ineffective, in elderly or high-risk patients in long-term care facilities and in households...
  50. ncbi request reprint Cefepime: a review of its use in the management of hospitalized patients with pneumonia
    Therese M Chapman
    Adis International Inc, Langhorne, Pennsylvania 19407, USA
    Am J Respir Med 2:75-107. 2003
    ..Other, less common, adverse events included pruritus, urticaria, nausea, vomiting oral candidiasis, colitis, headache, fever, erythema and vaginitis...
  51. ncbi request reprint Lansoprazole: in the management of gastroesophageal reflux disease in children
    Lesley J Scott
    Adis International Inc, Langhorne, Pennsylvania 10947, USA
    Paediatr Drugs 5:57-61; discussion 62. 2003
    ..The drug is generally well tolerated in children with GERD. In the largest study, the most common treatment-related adverse events occurring during therapy were constipation and headache...
  52. ncbi request reprint Spotlight on montelukast in asthma in children 2 to 14 years of age
    Richard B R Muijsers
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:225-8. 2002
    ..Montelukast is generally well tolerated. The frequency of adverse events in montelukast-treated children of all ages was comparable to that in patients receiving placebo...
  53. ncbi request reprint Oxcarbazepine: a review of its use in children with epilepsy
    Lynne Bang
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:557-73. 2003
    ..Nevertheless, the generally favorable tolerability profile and relatively low potential for drug interactions of oxcarbazepine make it a valuable option in the treatment of childhood epilepsy...
  54. ncbi request reprint 17 beta-estradiol/levonorgestrel transdermal system
    Toni M Dando
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 3:319-24. 2004
    ..The estradiol/levonorgestrel transdermal system was generally well tolerated. In two trials, application-site reactions were common in all treatment groups (estradiol/levonorgestrel, estradiol, and placebo)...
  55. ncbi request reprint Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris
    Caroline Fenton
    Adis International Limited, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:463-78. 2004
    ..The safety of calcipotriol/betamethasone dipropionate in patients treated for up to 1 year was generally good; fewer than 5% of patients experienced adverse events possibly associated with long-term corticosteroid use...
  56. ncbi request reprint Spotlight on estradiol and norgestimate as hormone replacement therapy in postmenopausal women
    Monique P Curran
    Adis International Limited, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 1:127-9. 2002
    ..In the meantime, continuous oral estradiol plus intermittent oral norgestimate can be regarded as an effective new option for HRT in postmenopausal women...
  57. ncbi request reprint Risedronate once a week
    Ngaire J White
    Adis International Inc, Yardley, Pennsylvania, 19067, USA
    Treat Endocrinol 2:415-20; discussion 421. 2003
    ..The tolerability profile (including the incidence of upper gastrointestinal adverse events) of risedronate 35mg once a week in women with postmenopausal osteoporosis, was similar to that of risedronate 5mg once daily...
  58. ncbi request reprint Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis
    Vicki Oldfield
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 6:189-208. 2006
    ..Thus, in accordance with current clinical guidelines, bosentan is a convenient, effective, and generally well tolerated agent for use in the first-line treatment of class III PAH or second-line treatment of class IV PAH...
  59. ncbi request reprint Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction
    C J Dunn
    Adis International Inc, Langhorne, Pennsylvania, USA
    Am J Cardiovasc Drugs 1:51-66. 2001
    ..94 and 1.66%, respectively). The rate of noncerebral bleeding was lower with tenecteplase than with alteplase (26.43 vs 28.95%; p = 0.0003). No causal link has been demonstrated between tenecteplase and allergic reactions in patients...
  60. ncbi request reprint Spotlight on topical pimecrolimus in atopic dermatitis
    Keri Wellington
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Clin Dermatol 3:435-8. 2002
    ..Topical pimecrolimus 1.0% provides a promising and well tolerated treatment option in the management of infants, children and adults with mild to moderate atopic dermatitis...
  61. ncbi request reprint The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions
    John Waugh
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 4:257-68. 2004
    ..The group receiving insulin was too small to draw meaningful conclusions...
  62. ncbi request reprint Flunisolide HFA
    John Waugh
    Adis International Inc, Langhorne, Pennsylvannia 19047, USA
    Am J Respir Med 1:369-72; discussion 373. 2002
    ..Flunisolide HFA was well tolerated in all trials. A long-term study found no suppression of adrenal function and minimal systemic effects were observed both in adults and children...
  63. ncbi request reprint Spotlight on adapalene in acne vulgaris
    John Waugh
    Adis International Inc, Yardley, PA 19067, USA
    Am J Clin Dermatol 5:369-71. 2004
    ..These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris...
  64. ncbi request reprint Clopidogrel: potential in the prevention of cardiovascular events in patients with acute coronary syndromes
    S E Easthope
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 1:467-74; discussion 475-6. 2001
    ..However, there was no difference between the two groups in the incidence of bleeding episodes that were considered to be life-threatening...
  65. ncbi request reprint Darbepoetin alfa: its use in anemia associated with chronic kidney disease
    Dean M Robinson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:327-43. 2005
    ....
  66. ncbi request reprint Memantine
    Blair Jarvis
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 20:465-76; discussion 477-8. 2003
    ..Adverse events (incidence in memantine recipients greater than in placebo recipients) occurring in patients with moderately severe to severe dementia included diarrhoea, insomnia, dizziness, headache and hallucination...
  67. ncbi request reprint Clofarabine: in pediatric patients with acute lymphoblastic leukemia
    Monique P Curran
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 7:259-64; discussion 265-6. 2005
    ..Capillary leak syndrome or systemic inflammatory response syndrome was reported in four patients...
  68. ncbi request reprint Clobetasol propionate foam, 0.05%
    E B Melian
    Adis International Inc, Langhorne, Pennsylvania, USA
    Am J Clin Dermatol 2:89-92; discussion 93. 2001
    ..Clobetasol foam 7 g/day for 2 weeks induced reversible suppression of the hypothalamic-pituitary-adrenal axis in 3 out of 13 patients (methodology of assessment not provided)...
  69. ncbi request reprint Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection
    Caroline Fenton
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 6:177-97. 2004
    ..The use of palivizumab in these other high-risk populations is likely to be determined as much by pharmacoeconomic considerations as by efficacy outcomes...
  70. ncbi request reprint Cilostazol: a review of its use in intermittent claudication
    Therese M Chapman
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 3:117-38. 2003
    ..Coadministration of cilostazol with aspirin or warfarin did not result in any clinically significant changes to coagulation parameters, bleeding time or platelet aggregation...
  71. ncbi request reprint Rotavirus vaccine (RotaTeq)
    Gillian M Keating
    Adis International Inc, Yardley, PA 19067, USA
    Paediatr Drugs 8:197-202; discussion 203-4. 2006
    ..Rotavirus vaccine and placebo were associated with serious adverse events in <3% of infants in either group...
  72. ncbi request reprint Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization
    Tim Ibbotson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 3:381-6. 2003
    ....
  73. ncbi request reprint Linezolid: in infants and children with severe Gram-positive infections
    Katherine A Lyseng-Williamson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:419-29; discussion 430-1. 2003
    ..Linezolid is generally well tolerated. The most common drug-related adverse events in the comparator-controlled trials were diarrhea, nausea, and headache; most events were mild to moderate in severity...
  74. ncbi request reprint Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive
    Susan J Keam
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 2:49-70. 2003
    ..A similar improvement in skin condition (acne, seborrhea) was observed in women receiving EE/DRSP or ethinylestradiol 35microg/cyproterone acetate 2mg in a randomized, double-blind trial...
  75. ncbi request reprint Spotlight on paricalcitol in secondary hyperparathyroidism
    Dean M Robinson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Endocrinol 4:185-6. 2005
    ..Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and children with chronic renal failure...
  76. ncbi request reprint Formoterol delivered by Turbuhaler: in pediatric asthma
    Susan M Cheer
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Paediatr Drugs 5:63-8; discussion 69. 2003
    ..Formoterol delivered by Turbuhaler was well tolerated in pediatric patients, with respiratory infection being the most commonly reported adverse event...
  77. ncbi request reprint Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection
    Nila Bhana
    Adis International Inc, 860 Town Center Drive, Langhorne, PA 19047, USA
    Paediatr Drugs 4:515-53. 2002
    ..Zidovudine was generally well tolerated as monotherapy in clinical trials of pediatric patients with HIV infection, and adverse events were similar to those reported in adults, with anemia and neutropenia being the most common...
  78. ncbi request reprint Bosentan
    Amitabh Prakash
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:335-43; discussion 343. 2002
    ..Those that occurred less frequently with bosentan 125 mg twice daily than with placebo included dizziness, worsening of symptoms of pulmonary arterial hypertension, cough and dyspnea...
  79. ncbi request reprint Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 65:827-58. 2005
    ....
  80. ncbi request reprint Spotlight on ranolazine in chronic stable angina pectoris
    M Asif A Siddiqui
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 6:357-9. 2006
    ..Nevertheless, ranolazine ER may well prove to be a useful alternative and adjunct to conventional hemodynamic antianginal therapy in the treatment of chronic stable angina...
  81. ncbi request reprint Spotlight on reteplase in thrombotic occlusive disorders
    Dene Simpson
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 21:65-8. 2007
    ....
  82. ncbi request reprint Adapalene: a review of its use in the treatment of acne vulgaris
    John Waugh
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:1465-78. 2004
    ..These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris...
  83. ncbi request reprint Spotlight on pegfilgrastim in chemotherapy-induced neutropenia
    James E Frampton
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:405-7. 2005
    ..Pegfilgrastim should, likewise, permit simplification of G-CSF-based stem cell mobilization and transplantation procedures...
  84. ncbi request reprint Spotlight on verteporfin in subfoveal choroidal neovascularisation
    Susan J Keam
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:203-9. 2004
    ..Approximately 5% of patients with occult with no classic subfoveal CNV secondary to AMD reported severe vision decrease within 7 days of treatment in clinical trials; 3 months later, several patients had recovered some of this loss...
  85. ncbi request reprint Saquinavir: a review of its use in boosted regimens for treating HIV infection
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Drugs 63:1299-324. 2003
    ....
  86. ncbi request reprint Voriconazole: in the treatment of invasive aspergillosis
    Richard B R Muijsers
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:2655-64; discussion 2665-6. 2002
    ..02 both comparisons) fewer treatment-related adverse events or serious adverse events. The incidence of visual disturbances was significantly (p < 0.001) higher with voriconazole than amphotericin B treatment...
  87. ncbi request reprint Novolizer: a multidose dry powder inhaler
    Caroline Fenton
    Adis International Limited, Auckland, New Zealand
    Drugs 63:2437-45; discussion 2447-8. 2003
    ..Most patients preferred it to previously used MDIs or DPIs. Only 4-5% found the taste feedback unacceptable. Physicians observed improved compliance over 4 weeks in 80% of patients with asthma using Novolizer...
  88. ncbi request reprint Intravenous esomeprazole
    Gillian M Keating
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 64:875-82; discussion 883. 2004
    ..Intravenous esomeprazole was generally well tolerated in patients with erosive oesophagitis, with a tolerability profile similar to that of the oral formulation...
  89. ncbi request reprint Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease
    Caroline Fenton
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1975-96. 2004
    ..The DPI combining a corticosteroid and long-acting beta2-agonist provides benefits over monotherapy and may encourage patient compliance in COPD...
  90. ncbi request reprint Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease
    Gillian M Keating
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 67:2383-405. 2007
    ..Thus, salmeterol/fluticasone propionate is an important option in the treatment of patients with COPD who are appropriate candidates for combination therapy with a long-acting bronchodilator and an inhaled corticosteroid...
  91. ncbi request reprint Paricalcitol: a review of its use in the management of secondary hyperparathyroidism
    Dean M Robinson
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand
    Drugs 65:559-76. 2005
    ..Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and children with chronic renal failure...
  92. ncbi request reprint Tramadol/paracetamol
    Karen McClellan
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:1079-86; discussion 1087-8. 2003
    ..5/325 mg provided similar efficacy to that of codeine/paracetamol 30/300 mg in patients with chronic back pain in a 4-week, randomised, double-blind trial (a maximum of 10 tablets or capsules per day of the active drug)...
  93. ncbi request reprint Cetirizine: a review of its use in allergic disorders
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 64:523-61. 2004
    ..Cetirizine did not have any adverse effects on cognitive function in adults, or cognitive function, behaviour or achievement of psychomotor milestones in paediatric patients. Cetirizine was not associated with cardiotoxicity...
  94. ncbi request reprint Cinacalcet hydrochloride
    Julia A Barman Balfour
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 65:271-81. 2005
    ..Cinacalcet HCl was generally well tolerated in clinical trials. Most treatment-emergent adverse events were mild to moderate in severity...
  95. ncbi request reprint Intravenous ibandronate: in the treatment of osteoporosis
    Katherine F Croom
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1593-601; discussion 1602-3. 2006
    ..IV ibandronate was generally well tolerated in clinical trials. Treatment-related adverse events included musculoskeletal events and transient influenza-like symptoms, the latter mainly associated with the first dose...
  96. ncbi request reprint Oxybutynin extended-release: a review of its use in the management of overactive bladder
    M Asif A Siddiqui
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 64:885-912. 2004
    ..Hence, given its overall efficacy/tolerability profile and dosage flexibility, oxybutynin ER provides an excellent treatment option in the first-line pharmacotherapy of OAB...
  97. ncbi request reprint Entecavir: a review of its use in chronic hepatitis B
    Dean M Robinson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1605-22; discussion 1623-4. 2006
    ..In addition, the tolerability profile of entecavir was generally similar to that of lamivudine. Thus, entecavir is a primary option in the treatment of chronic HBV infection in both nucleoside-naive and lamivudine-refractory patients...
  98. ncbi request reprint Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2129-35; discussion 2136-7. 2005
    ..Lansoprazole was generally well tolerated in children and adolescents, with the most common treatment-related adverse events being gastrointestinal events and headache...
  99. ncbi request reprint Donepezil: in vascular dementia
    David R Goldsmith
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 20:1127-36. 2003
    ..Donepezil was generally well tolerated in patients with VaD. Most adverse events were mild to moderate in nature, with diarrhoea and nausea being the most common...
  100. ncbi request reprint Esomeprazole: a review of its use in the management of acid-related disorders
    Lesley J Scott
    Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland 10, New Zealand
    Drugs 62:1503-38. 2002
    ..Few patients discontinued therapy because of treatment-emergent adverse events (<3% of patients), with very few (<1%) drug-related serious adverse events reported...
  101. ncbi request reprint Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis
    M Asif A Siddiqui
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2179-208. 2005
    ..Nonetheless, infliximab, like other biological agents, is a valuable treatment option in patients with moderately to severely active Crohn's disease (including fistulising disease) or rheumatoid arthritis (including early disease)...